New analgesic combines an opiate with an NSAID

Skudexa is an oral analgesic containing a combination of tramadol and dexketoprofen for the treatment of moderate to severe pain.

Opium poppies (Papaver somniferum) are used as a source of opiate narcotics. | TED KINSMAN/SCIENCE PHOTO LIBRARY
Opium poppies (Papaver somniferum) are used as a source of opiate narcotics. | TED KINSMAN/SCIENCE PHOTO LIBRARY

Skudexa combines the effects of tramadol, a centrally acting synthetic opioid analgesic with those of the non-opioid analgesic dexketoprofen, an established NSAID.

The novel combination is licensed for the short-term treatment of moderate to severe acute pain in adults whose pain is considered sufficient to warrant use of the two analgesics concurrently.

The recommended dose is one tablet (tramadol 75mg/dexketoprofen 25mg) taken as needed, with a minimum dosing interval of eight hours, up to a maximum of three tablets daily. The duration of treatment should be limited to the symptomatic period and should not exceed five days.

In elderly patients an initial daily maximum dose of two tablets should be observed. Once good general tolerance has been ascertained the maximum daily dose can be increased to three tablets daily.

Skudexa is not recommended for use in children or adolescents due to an absence of safety and efficacy data relating to these populations. The product is contraindicated for use in women who are pregnant or breastfeeding.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

intelog summary of NICE COPD guidance updated

intelog summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference intelog...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...